Edison Publishes Research Note On Cardio3 BioSciences, US IPO Intended
LONDON, April 10, 2015 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, announces coverage of a company intending to conduct a registered public offering in the United States.
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
Cardio3 has disclosed an aggressive and ambitious clinical trial programme to develop its novel Natural Killer CAR therapy. Currently starting a Phase I in AML and MM, Cardio3 aims to start one solid tumour trial per quarter once an initial AML/MM efficacy signal is detected. This potentially moves Cardio3 into large, valuable indications, well away from the crowded space around ALL. Cardio3's core value is based on C-Cure cardiac cell therapy. Adding CAR AML and MM therapies takes the indicative value to €985m, €121/share. Solid tumour indications might add €519m, €64/share, but are not currently included as still preclinical. Comparable US CAR companies have high valuations on limited clinical data: Juno $5.2bn; Kite $2.4bn. Cardio3 has announced a US IPO.
To download this report, please click here.
All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn: http://www.linkedin.com/company/edison-investment-research
Twitter: http://www.twitter.com/Edison_Inv_Res
YouTube: http://www.youtube.com/edisonitv
For more information please contact:
Dr John Savin
Edison Investment Research
+44(0)20-3077-5735
Christian Glennie
Edison Investment Research
+44(0)20-3077-5727
healthcare@edisongroup.com
SOURCE Edison Investment Research
Help employers find you! Check out all the jobs and post your resume.
Edison Investment Research, a leading international investment research firm, announces coverage of a company intending to conduct a registered public offering in the United States.
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
Cardio3 has disclosed an aggressive and ambitious clinical trial programme to develop its novel Natural Killer CAR therapy. Currently starting a Phase I in AML and MM, Cardio3 aims to start one solid tumour trial per quarter once an initial AML/MM efficacy signal is detected. This potentially moves Cardio3 into large, valuable indications, well away from the crowded space around ALL. Cardio3's core value is based on C-Cure cardiac cell therapy. Adding CAR AML and MM therapies takes the indicative value to €985m, €121/share. Solid tumour indications might add €519m, €64/share, but are not currently included as still preclinical. Comparable US CAR companies have high valuations on limited clinical data: Juno $5.2bn; Kite $2.4bn. Cardio3 has announced a US IPO.
To download this report, please click here.
All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn: http://www.linkedin.com/company/edison-investment-research
Twitter: http://www.twitter.com/Edison_Inv_Res
YouTube: http://www.youtube.com/edisonitv
For more information please contact:
Dr John Savin
Edison Investment Research
+44(0)20-3077-5735
Christian Glennie
Edison Investment Research
+44(0)20-3077-5727
healthcare@edisongroup.com
SOURCE Edison Investment Research
Help employers find you! Check out all the jobs and post your resume.